Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | The potential of PARP inhibitors in ovarian cancer: PAOLA-1, PRIMA & VELIA

Jonathan Ledermann, MD, FRCP, University College London, London, UK, discusses three Phase III clinical trials exploring the potential of PARP inhibitors in the frontline therapy of ovarian cancer. The PAOLA-1/ENGOT-ov25 trial (NCT02477644) studied the use of olaparib plus bevacizumab, while the PRIMA/ENGOT-OV26/GOG-3012 trial (NCT02655016) aimed to assess the efficacy of niraparib, and the VELIA/GOG/3005 trial (NCT02470585) evaluated the efficacy of veliparib. Prof. Ledermann believes that we are going to see much greater use of PARP inhibitors in the first-line setting of ovarian cancer treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.